PhRMA names new chairman
WASHINGTON The Pharmaceutical Research and Manufacturers of America elected Pfizer president and CEO Jeffrey Kindler as its board chairman Thursday at the trade organization’s annual meeting in Washington.
PhRMA also elected Sanofi-Aventis CEO Christopher Viehbacher as chairmen-elect of the board of directors and Eli Lilly & Co. president, CEO and chairman John Lechleiter as board treasurer. Kindler succeeds AstraZeneca executive director and CEO David Brennan as chairman.
“Great leadership requires patients, decisiveness, intelligence, execution and compassion,” PhRMA president and CEO Billy Tauzin said. “David encompasses all of these qualities and much more.”
PositiveID releases white paper about the health, economic burdens of diabetes
DELRAY BEACH, Fla. PositiveID has published a white paper that describes the health and economic burden of diabetes on Americans and the U.S. economy, the company said Wednesday.
“Fixing the Black Hole in Diabetes Management” discusses how patient care and overall health improves when there is a high quality of patient-clinician collaboration. Additionally, PositiveID noted that diabetics who follow recommended self-monitoring blood-glucose testing-level guidelines may not share the test results with their healthcare providers — the test results are not being used to improve glycemic control and achieve long-term goals, thus getting lost in a “black hole.”
PositiveID pointed out that the use of such monitoring systems as its iGlucose system, which uses wireless SMS messaging to automatically communicate a diabetic’s glucose levels in real-time, can be beneficial to diabetic patients. Citing a a 2009 study, “Excessive Hospitalizations and Its Associated Economic Burden among People with Diabetes in the United States,” found that in 2005, hospital charges alone and medical costs for individuals with diabetes exceeded $171 billion and $90 billion, respectively.
Scott Silverman, PositiveID chairman and CEO said, “We believe the benefits of the iGlucose system are obvious. It can provide improved health outcomes through real-time disease management, simplifying patients’ lives and enhancing vital communication between patients and their healthcare providers. iGlucose also has the ability to decrease fraud and healthcare costs for providers and insurers by automatically creating compliant patient testing logs, which are required to comply with Medicare Part B reimbursement regulations.”
Pending court ruling, Teva to delay marketing Temodar generic
JERUSALEM Teva Pharmaceutical Industries will start marketing its version of a brain tumor drug only if the Federal Circuit of the U.S. District Court upholds a ruling that declared the branded version’s patent unenforceable, Teva announced Wednesday.
The generic drug maker said it had entered an agreement with Schering, now part of Merck & Co., whereby it will market the drug only if the Federal Circuit upholds the U.S. District Court for the District of Delaware’s January ruling that would allow Teva to market a generic version of Schering’s Temodar (temozolomide). The regulatory approval application for the drug was originally filed by Barr Labs, which Teva acquired in 2008.
The agreement also gives Teva to begin selling its version of the drug in August 2013.